Webinar: 2020 Guideline: Advanced Prostate Cancer (2020)

June 30, 2020

Course Director: Michael S. Cookson, MD, MMHC

This course will review the important and newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive (HSPC) and Castration-Resistant Prostate Cancer (CRPC). This includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of M1 HSPC and non-metastatic MO CRPC. Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines. Also, the role of genetic testing (germline and somatic) in the evaluation of M1HSPC and CRPC, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA Advanced, Metastatic and CRPC guidelines in those instances. This course will be a benefit to practicing urologists, oncologists, advanced practice providers, as well as residents/fellows and clinicians preparing for their certification and re-certification exams, respectively.

Acknowledgements:

This educational activity is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

Upon completion of this activity, course participants will be able to:

  1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).
  2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
  3. Describe the indications and combinations for treatment with approved agents in the management of mHSPC.
  4. Describe the sequencing and indications for active treatment with approved agents in the management of nmCRPC.
  5. Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines.
  6. Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice.
  7. Identify the role of genetic testing in men with advanced, metastatic and CRPC.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
06/19/2020
Course expires: 
06/30/2023
Event starts: 
06/30/2020 - 10:00am EDT
Event ends: 
06/30/2020 - 11:30am EDT
Part of: 
Summer School Webinar Series (2020)
Add to calendar: 
Rating: 
0

Agenda

10:00 am   Welcome, Housekeeping Notes

10:05 am   Knowledge Assessment

10:10 am   Scientific Program

                    William D. Lowrance, MD, MPH

                    Adam Kibel, MD

                    Michael Cookson, MD, MMHC

                    David Jarrard, MD

11:15 am   Q&A

11:30 am  Webinar ends

2020 Guideline: Advanced Prostate Cancer (2020) will be held virtually on Tuesday, June 30 at 10 AM EST.

***Instructions***

  1. Click the "Register" tab.
  2. If prompted, click “update your profile”. Otherwise, click “Take Course”.
  3. Click “Start” under Live Webinar in the Course Progress pane.
  4. Click "Join Webinar".

Education Council Disclosures

PDF icon EC Disclosures _June 1 20 through Dec 31 20_2.pdf

AUA Office of Education Staff has nothing to disclose.

 

Course Director(s)

Michael Cookson, MD

has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.
has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
Faculty(s)

David Jarrard, MD

has no relevant financial relationships to disclose at this time.

Adam Kibel, MD

has a financial relationship (Other) with advantagene;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with ConfirmMDx;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Insight Diagnositics;.
has a financial relationship (Other) with advantagene;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Profound;.
has a financial relationship (Independent contractor) with Insight Diagnositics;.
has a financial relationship (Independent contractor) with ConfirmMDx;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Profound;.

William Lowrance, MD

has a financial relationship (Stock) with Stream Dx;.
has a financial relationship (Stock) with Stream Dx;.
has a financial relationship (Other) with Myriad Genetics;.
has a financial relationship (Other) with Myriad Genetics;.
has a financial relationship (Other) with Myriad Genetics;.
has a financial relationship (Other) with Myriad Genetics;.
has a financial relationship (Stock) with Stream Dx;.
has a financial relationship (Stock) with Stream Dx;.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA Participant Information and Policies

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.

REPRODUCTION PERMISSION: 

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

To join the webinar:

  1. Click on the TAKE COURSE button.
  2. Click “Start” under Live Webinar in the Course Progress pane.
  3. Click "Join Webinar".